The V antigen (LcrV) of the plague bacterium Yersinia pestis is a potent protective protein that is considered as a vaccine component for humans. LcrV mediates the delivery of Yop toxins into host cells and upregulates TLR2-dependent IL-10 production.
Introduction
The plague caused by Yersinia pestis is the most devastating bacterial infection known to man [1] . Y. pestis recently evolved from Yersinia pseudotuberculosis, which diverged from Yersinia enterocolitica about 50 million years ago [2] . All three species share an ~70-kb plasmid (termed pCD in Y. pestis [3] and pYV in enteropathogenic Y. pseudotuberculosis and Y. enterocolitica) that encodes the V antigen (LcrV), yersiniae outer proteins (Yops), and an attendant type 3
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A N U S C R I P T 3 secretion system (T3SS). The functions of T3SS are activated by pCD/pYV-encoded LcrF (VirF in enteropathogenic yersinia) [4] at 37ºC [5] and expressed upon host cell contact [6] or residence in Ca 2+ -deficient medium [7] and host fluids [8] . The most important feature of the plague is that it is a rapidly progressing disease, suggesting that Y. pestis prevents the activation of the innate immune response to infection as first shown for pCD-dependent downregulation of proinflammatory cytokines [9] . LcrV is a multifunctional protein and serves as a major regulator and effector of virulence. At the first stage of plague pathogenesis, LcrV acts as a short-term weapon of Y. pestis [10, 11] . LcrV forms a tip on the YscF nanotube of T3SS injectosome [12] and mediates translocation of Yop effectors into the target cells [13] for the initiation of bacterial growth in host organs and the buildup of bacterial cells that release sufficient amounts of secreted LcrV to induce effective levels of interleukin 10 (IL-10) at the next stage of pathogenesis, when it acts as a long-term weapon for Y. pestis [10, 11, 14] . This strategy also involves the production of noninflammatory lipopolysaccharide [15] , degradation of those Yops that fail to undergo translocation into the host cell cytoplasm [16] , inhibition of host MAPK kinase and NF-kB pathways by YopJ, resulting in apoptosis of professional phagocytes [17] [18] [19] , and induction of mitochondrial-dependent apoptosis of T-cells by YopH [20] or by YpkA [21] .
Deletion of YopJ did not result in decreased virulence of Y. pestis, systemic spread, or colonization levels in the spleen and blood [22] . At the same time, deletion of LcrV converted virulent strains of Y. pestis into avirulent ones [23, 24] . Although antibodies to Yop proteins could be found in the sera of both people and animals that survived a plague infection or were vaccinated with live plague vaccine, their protective potential is insufficient to be used in a subunit vaccine [25] . In contrast, the passive transfer of both LcrV-specific polyclonal or monoclonal antisera protected experimental animals against bubonic and pneumonic plague [23, A C C E P T E D M A N U S C R I P T 4 24, 26-32] . Sub-unit vaccines based on LcrV or LcrV+F1 proteins provided a high degree of protection in mice, guinea pigs, and nonhuman primates [33] [34] [35] [36] [37] [38] [39] [40] [41] .
Y. pestis replicates whiting lymphoid tissues. Because LcrV derivatives and anti-LcrV antibodies are being developed for prevention and prophylaxis against plague in humans, it is important to better understand the detailed mechanisms of all effects of LcrV, their relative importance in plague pathogenesis and inhibiting of Yops effects, such as the target-cell killing of human T lymphocytes prevented by anti-LcrV antibodies. Earlier we demonstrated that LcrV possesses two non-cooperative binding domains (LEEL [32] [33] [34] [35] and DEEI 203-206 ) capable of recognizing human IFN-γ but not mouse IFN-γ bound to its receptors (IFN-γ R-IFN-γ) on human U-937 cells and human alveolar macrophages [42] . Human IFN-γ, but not mIFN-γ, possessed a GRRA 138-141 site on the C-terminus of the molecule responsible for the high-affinity specific binding of LcrV [42] . The purpose of the present study was to obtain information regarding the specificity and avidity of the interaction between LcrV and hIFN-γ bound to its receptors on the surface of human primary thymocytes and Jurkat T-leukemia cells. We show here that LcrV uses
receptor-bound hIFN-γ for initiation of apoptosis of human T-cells. Monoclonal anti-LcrV antibodies completely blocks the programmed death of human T-cells induced by LcrV and
LcrV .
Materials and Methods

Recombinant Proteins
LcrV (defined in Figure 1A ) was produced as described previously [42] using lcrV encoded within the lcrGVH-yopBD operon of pCD1 from the Y. pestis strain KIM [43] . After amplification with PCR using sites for EcoRI and BamHI, lcrV was inserted into the vector
pRSET A (Invitrogen, Carlesbad, CA) opened with BamHI and EcoRI. This construct, expressed in Escherichia coli BL21(DE3), encoded N-terminal hexahistidine, an enterokinase cleavage site, and then LcrV in its entirety. Similar engineering of E. coli BL21(DE3) transformed with pVHB62 encoding LcrV 68-326 has been described [36] . LcrV and LcrV 68-326 encoded by these constructs were induced by IPTG, purified to homogeneity by Ni-affinity chromatography, and then freed of hexahistidine by treatment with enterokinase [36] . Homogeneous dimers of LcrV and LcrV were purified by gel-filtration on Sepharose CL-4B column (Sigma Chemical Co., St. Louis, MO). Endotoxin was removed from the preparations of purified protein using polymyxin B-agarose (Sigma). Endotoxin-depleted preparations contained 0.16 ± 0.03 pg (mean ± SE, n =5) of endotoxin/µg of protein as measured by the Limulus amebocyte lysate assay system. Preparations of recombinant human IFN-γ (antiviral activity of 2.0×10 7 U/mg) and Cterminally truncated h∆IFN-γ (antiviral activity 1.5×10 7 U/mg) lacking six C-terminal amino acids as defined in Figure 1C and mouse IFN-γ were kindly supplied by Dr. V. Fedyukin (JSC "ImmunoPharm", Obolensk, Russia). Circular dichroism spectra of hIFN-γ and h∆IFN-γ were almost identical. Highly purified human IFN-α2 was purchased from PeproTech, Ltd. (London, U.K.). Purity of recombinant proteins was monitored by SDS-PAGE and silver staining [44] .
Synthetic Peptides
Derivatives of LcrV ( Figure 1B) were synthesized as described [42] using a solid-phase model 9500 peptide synthesizer (Biosearch Technologies, Inc., Novato, CA) and purified by HPLC chromatography. The purity and sequence of these peptides were confirmed by amino acid analysis and mass spectrometry.
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Cell Cultures and Growth Conditions
Normal human thymocytes were obtained from children aged up to 4 months that underwent thymus removal during cardiac surgery (Cardiocenter, Moscow, Russia). During the period of our studies, Cardiocenter had a protocol approved by its ethical committee for the surgical treatment of congenital heart diseases, according to which, in order to get the access to the heart, a part of the sternum was removed along with a part of the thymus. After performing a heart surgery, the post-surgical material was disposed. The study of the properties of thymocytes isolated from post-surgical material was approved by the ethical committee of Cardiocenter and Ethical Committee of the Institute of Immunological Engineering. Suspension of individual cells was obtained via thymus disintegration and following purification using gradient centrifugation in Ficol Hypaqu. Thymocytes were washed thrice in an RPMI 1640 medium containing 2% fetal calf serum (FCS). Cell vitality was determined using methylene blue and reached 98% [45] .
Jurkat T-leukemia cells were kept at logarithmic growth in TPMI 1640 medium supplemented with 10% FCS, 2 mM L-glutamin,1 mM sodium pyruvate, nonessential amino acids and 100 unit/ml each penicillin G and streptomycin.
Monoclonal Mouse Anti-LcrV Antibodies
Peptides from LcrV [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] and LcrV 193-210 (defined in Figure 1B ), which contained active sites LEEL and DEEI responsible for the binding to human IFN-γ, were resynthesized for including a C-terminal cysteine and conjugated to keyhole limpet hemocyanin (KLH) through this additional residue. The peptide-carrier conjugates were purified by gel-filtration and used for elaboration of mouse monoclonal antibodies.
Polyclonal Rabbit Anti-LcrV and Anti-hIFN-γ Antibodies
Human IFN-γ and LcrV protein were adsorbed to aluminum hydroxide. The conjugates were used for the immunization of rabbits. Two groups of rabbits up to 3 animals (chinchilla, 2.5 kg) in each group were used for immunization and obtaining anti-hIFN-γ and anti-LcrV sera. The titer of rabbit sera for hIFN-γ and LcrV had an average value of 500,000. Polyclonal anti-hIFN-γ and anti-LcrV antibodies were elaborated by chromatography on the protein A-Cepharose column. 
Radiolabeling of Ligands
Binding of the Radioactive Ligands the Cells
Normal human thymocytes or Jurkat T-leukemia cells were collected, washed three times with RPMI-1640 medium, and then adjusted to a concentration of 10 7 per mL of the same medium.
Radioactive ligands were then added to individual cultures (total volume of 300 µL), which were then incubated for either 1 h at 4°C or 15 min at 37°C. Thereafter, 50 µL of the cell culture was layered on 250 µL of an n-dibutylphthalate/bis (2-ethylhexyl)-phthalate mixture (1:1 v/v) and centrifuged for 2 min at 14,000 g. Radioactivity in the resulting precipitate was measured using a model 1275 MINI GAMMA counter (LKB WALLAC, Sweden). Nonspecific binding of radioactive ligands to cells or plastic plates was determined by incubation in 10,000-fold excess of corresponding unlabeled ligand and was equal to 25-27% of the total (specific plus 
Apoptotic Activity of LcrV
LcrV-induced apoptosis of human thymocytes and Jurkat T-leukemia cells was measured by determining light scattering and red fluorescence as described earlier [47] . Thymocytes were cultivated for 24 h as described above and then exposed to LcrV with or without hIFN-γ followed by continued incubation for another 24 h. The cells were then fixed with 70% ethanol to permeabilize the cell membrane and suspended into PBS containing triton-100 (Sigma).
Propidium iodide (Sigma) diluted in PBC (containing 0.1% triton X-10 and 0.1% sodium citrate) was then added to this preparation to yield a final concentration of 0.05 mg/ml. Analysis was undertaken with a FACS Calibur Fluid Cytofluorimeter (Becton-Discinson, USA with argon laser (488 nm wavelength) using forward and side light scattering). Red fluorescence was evaluated by propidium iodide for 10,000 cells and expressed in histograms as peak M1 (which is the hypodiploid peak in percent that characterizes apoptotic cells in which DNA is fragmented, and as a result, after washing of these cells, they contain an amount of DNA below the diploid chromosome <2N), peak M2 (which is the diploid peak in percent that characterizes the resting cells in the phase G0 and the cells that are in the presynthetic phase of the G1 cell cycle and which contain the amount of DNA corresponding to the diploid set of chromosomes of 2 N), and peak M3 (a proliferation peak in percentage that characterizes the proliferative potential of cells
in the pre-intolerant phase of G2 and mitosis phase M when the number of chromosomes and the DNA content is doubled by 4N). Data analysis was conducted using the CELLQUEST software.
Computational analysis of intrinsic disorder propensity
The amino acid sequence of human IFN-γ protein was used for the sequence-based analysis of intrinsic disorder predisposition. The per-residue intrinsic disorder of the protein was evaluated by several commonly used disorder predictors, such as PONDR ® VLXT [48] , PONDR ® VSL2 [49] , PONDR ® VL3 [50] , PONDR ® FIT [51] , and IUPred [52] . These tools were selected based on their specific features. PONDR ® VSL2 [49] is one of the more accurate stand-alone disorder predictors [49, 53, 54] . PONDR ® VL3 is characterized by high accuracy for predicting long intrinsically disordered regions [55] , and PONDR ® VLXT is known to have high sensitivity to local sequence peculiarities and can be used for identifying disorder-based interaction sites [56] .
IUPred was designed to recognize intrinsically disordered protein regions (IDPRs) from the amino acid sequence alone based on the estimated pairwise energy content [52, 57] . Finally, the metapredictor PONDR ® FIT is more accurate than each of its component predictors (PONDR ® VLXT [56] , PONDR ® VSL2 [49] , PONDR ® VL3 [50] , FoldIndex [58] , IUPred [52] , and TopIDP [59] ) [51] ).
Results
The human IFN-γ molecule is a noncovalent homodimer that consist of two identical 17-kDa polypeptide chains [60] . The crystal structure of hIFN-γ confirmed its dimeric nature and revealed that two polypeptides self-associate in an antiparallel fashion, producing a molecule that exhibits a two-fold axis of symmetry [61] . Only the homodimeric form of hIFN-γ demonstrates
10 full biological activity [62] . In our experiments, we used LcrV as a non-covalent homodimer that consist of two identical 35.8 kDa polypeptide chains and LcrV 68-326 as a non-covalent homodimer that consist of two identical 28.5 kDa polypeptide chains (data not shown).
Radioactive 125 I-LcrV and 125 I-LcrV (defined in Figure 1A ) did not interact with hIFN-γ and h∆IFN-γ (the amino acid sequences of C-terminal regions of these proteins are shown in Figure 1C ) immobilized on the surface of plastic plate ( Table 1 ). Radioactive 125 I-hIFN-γ and 125 I-h∆IFN-γ did not interact with LcrV and LcrV 68-326 immobilized on the surface of plastic plate ( Table 1) . These results provide strong evidence that LcrV and LcrV Table 2 ). The C-terminal regions of recombinant hIFN-γ, hΔIFN-γ, and mIFN-γ contain the KRKRS amino acid sequence ( Figure   1C ) responsible for the high-affinity binding to IFN-γR [63, 64] . However, only hIFN-γ but not hΔIFN-γ and mIFN-γ contains the GRRA amino acid sequence in its C-terminal region ( Figure   1C ). This motif is responsible for the high-affinity interactions with LcrV or LcrV 68-326 [42] . (Figure 2 A, B) . At simultaneous addition of LcrV and hIFN-γ into the culture medium, the hypodiploid peak was increased, reflecting the induction of apoptosis in Jurkat T-cells ( Figure   2C ) in comparison to the experiments where LcrV alone (Figure 2A ) or hIFN-γ alone ( Figure   2B ) were added into the medium. The diploid peak and proliferation peak were considerably lower ( Figure 2C 
Discussion
To assess the protective properties of new anti-plague vaccines for humans, mice are most often used as a relevant model organism. The terminal murine plague is an anti-inflammatory disease [9] , and LcrV contributes to this process [14] by upregulating IL-10 [65, 66] , a powerful anti-inflammatory cytokine that prevents expression of a variety of host inflammatory factors [67, 68] . The obtained results indicate that LcrV and LcrV can efficiently interact with the hIFN-γ immobilized on the IFN-γ receptors of Jurkat T-cells or human thymocytes, but not with the hIFN-γ in solution or with the hIFN-γ immobilized on plastic plates. These observations suggest that the two binding sites GRRA 138-141 responsible for interaction of the hIFN-γ homodimers with LcrV and LcrV are not accessible in solution or after immobilization of hIFN-γ homodimers on the plastic plates. In contrast, the binding sites LEEL [32] [33] [34] [35] and DEEI [203] [204] [205] [206] on the LcrV molecule are accessible in solution [69] .
The crystal structure of a complex between human IFN-γ homodimer and two extracellular domains of soluble IFN-γ receptor α-chains was resolved [70, 71] . Figure 3A represents structure of this complex and show that each IFN-γ monomer contacts one soluble receptor α-chain. As a result, an IFN-γ homodimer serves as a linker between the two IFN-γ receptor α-chains (IFN-γRα-chains). According to Walter and colleagues [70] , each protomer of the IFN-γ homodimer consists of six helices (A, B, C, D, E, and F) related by a non-crystallographic twofold axis.
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13 Figure 3B shows that the human IFN-γ homodimer is characterized by a highly intertwined structure, where two C-terminal α-helices (E and F) of one protomer interact with the helices A, B, C, and D of another protomer. It was also pointed out that the 13 residue-long AB loop of one protomer encircle the α-helix F of another protomer [70, 71] . Also, in both protomers, the main chain after the α-helix F (after residue 122) extends to the solvent away from the protein molecule [70] . Overall, it was pointed out that the dimeric structure of human IFN-γ is stabilized by the intertwining of helices across the subunit interface with multiple intersubunit interactions [61] . Such intertwined structure of the homodimer suggests that it is formed as a result of binding-induced folding [72] [73] [74] . In other words, it seems that the human IFN-γ is not stable in its monomeric form. In agreement with this hypothesis, Figure 3C shows the results of the intrinsic disorder propensity analysis of this protein by a set of commonly used disorder predictors, PONDR ® VLXT, PONDR ® VL3, PONDR ® VSL2, PONDR ® FIT, IUPred_short, and
IUPred_long. This analysis suggested that the C-terminal half of human IFN-γ is indeed characterized by high intrinsic disorder predisposition, and the C-tail of this protein (approximately the last 20 residues) is entirely disordered (see Figure 3C ). However, it is known that the intrinsically disordered proteins or proteins with intrinsically disordered regions are frequently involved in protein-protein interactions and molecular recognitions [56, [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] and undergo at least partial disorder-to-order transitions upon binding [56, 79, [87] [88] [89] [90] [91] [92] [93] [94] . These observations were utilized to develop computational tools for the identification of potential disorder-based binding sites. Application of one of such tools, the ANCHOR algorithm [95, 96] , revealed that human IFN-γ contains several such potential binding sites, including C-terminally [63, 64] .
Comparison of the crystal structures of IFN-γ homodimer alone (PDB ID: 1HIG) [61] , or in complex with two extracellular domains of soluble IFN-γ receptor α-chains was resolved (PDB ID: 1FG9) [70, 71] , or complexed with the IFN-γ-binding protein from Ectromelia virus (ECTV) (IFN-γBP ECTV ; PDB ID: 3BES) [97] revealed that although interaction with these partners virtually did not affect the structure of the "body" of the IFN-γ molecule, the C-terminal tail underwent noticeable structural changes (see Figure 3D ). In fact, in the resolved crystal structure of the IFN-γ homodimer alone (PDB ID: 1HIG) [61] , the C-tail contains only the residues AELSPA, whereas the major part of the C-terminal region (residues AKTGKRKRSQMLFRGRRASQ) is absent (see blue structure in Figure 3D ), despite the fact that the full-length mature protein was used in these crystallization experiments. The fact that the C-terminal residues are not visible in the corresponding crystal structure (i.e., represent a missing electron density region) indicates their high conformational flexibility. In a complex of the human IFN-γ homodimer with two extracellular domains of IFN-γR α-chains (PDB ID: 1FG9) [70, 71] , the resolved structure of the IFN-γ C-tail is extended to include residues AELSPAAKT (see red structure in Figure 3D ), whereas the remaining part of C-tail is still missing. Finally, complexation with IFN-γBP ECTV (PDB ID: 3BES) [97] caused the most noticeable structuration of the IFN-γ C-tail, since in this complex, the resolved structure of this region includes residues AELSPAAKTGKRKRS, where an additional short α-helix is formed (see green structure in Figure 3D ). These data clearly indicate that the peculiarities of structural organization of the Ctail of human IFN-γ depend strongly on a binding partner. Therefore, based on the analysis of the available structural information, one can hypothesize that, after interaction of the human IFN-γ
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The IFN-γ receptor α-chain is expressed at moderate levels on the surfaces of nearly all cells of the human organism, being especially abundantly expressed on the surface of T-cells. The gene of the IFN-γ receptor α-chain (IFNGR1) belongs to housekeeping genes, and the expression of this gene appears to be constitutive [98] . In contrast, the expression of the IFN-γ receptor β chain in certain cell types is regulated by external stimuli. Regulation of the IFN-γ receptor β chain gene is a critical factor in determining IFN-γ responsiveness in certain cells. Overall, both IFN-γ receptors play a critical role in providing innate and adaptive resistance of the host to microbial infections [99] [100] [101] . Modifications in the human IFN-γ receptor resulted in a severe susceptibility of hosts to weakly pathogenic mycobacterial species [102, 103] . The IFN-γ receptor α chain knock-out mice (IFN-γ-Rα -/-) displayed a greatly impaired ability to resist infection caused by a variety of microbial pathogens [99, 101] .
We show here that the interaction of LcrV and LcrV Apoptosis induction in T-cells is most commonly initiated in response to death receptor ligation, peptideresulting in activation of caspase-8 (extrinsic pathway) [104] , or cellular stress followed by mitochondrial release of cytochrome c and subsequent activation of caspase-9
(intrinsic pathway) [105] . Apoptosis activation can be a very complex process, making it difficult to specifically implicate a single pathway responsible for the induction of cell death.
The molecular mechanisms that initiates apoptosis of human T-cells after LcrV interaction with
receptor-bound human IFN-γ will be elucidated in our subsequent studies. (A) Primary structure of LcrV from Y. pestis KIM, [3] where the amino acids of the construct (LcrV ) first used to prove ability to raise protective antibodies [28] and demonstrate amplification of IL-10 (ref. [66] ) are shown in red. Amino acid sequences used to generate synthetic peptides are shown in bold. LEEL and DEEI binding sites responsible for the interaction with receptor-bound hIFN-γ (ref. [42] ) are underlined; 
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